5 Insightful Analyst Questions From NeoGenomics’s Q1 Earnings Call
NeoGenomics’ first quarter results saw revenue growth, but sales came in below market expectations, leading to a significant negative market reaction. Management attributed the quarter’s performance to strong clinical test volume growth and increased adoption of next-generation sequencing (NGS) products, partially offset by continued headwinds in the non-clinical pharma segment. CEO Tony Zook described the quarter as confirming existing strengths, highlighting, “The NGS growth above market…was c